Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Takeda Pharmaceutical Company Limited
  6. Summary
    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
3700 3697 3700 3756 3682 Last
4708400 3733600 3434700 4236400 6247600 Volume
-0.27% -0.08% +0.08% +1.51% -1.97% Change
Estimated financial data (e)
Sales 2022 3 356 B 30 590 M 30 590 M
Net income 2022 303 B 2 765 M 2 765 M
Net Debt 2022 3 089 B 28 162 M 28 162 M
P/E ratio 2022 19,1x
Yield 2022 4,89%
Sales 2023 3 373 B 30 750 M 30 750 M
Net income 2023 364 B 3 315 M 3 315 M
Net Debt 2023 2 722 B 24 815 M 24 815 M
P/E ratio 2023 16,0x
Yield 2023 4,89%
Capitalization 5 778 B 52 641 M 52 671 M
EV / Sales 2022 2,64x
EV / Sales 2023 2,52x
Nbr of Employees 47 099
Free-Float 99,3%
More Financials
Company
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system... 
Sector
Pharmaceuticals
Calendar
07/30 | 02:00amEarnings Release
More about the company
Ratings of Takeda Pharmaceutical Company Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
07/30TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Three-month Peri..
PU
07/30TAKEDA PHARMACEUTICAL : Q1 Core EPS Drops, Revenue Rises
MT
07/30Takeda Pharmaceutical's First-Quarter Net Profit More Than Doubled
DJ
07/30TAKEDA PHARMACEUTICAL : Summary of Financial Statements for the Three-month Peri..
PU
07/30TAKEDA PHARMACEUTICAL : Delivers Solid First Quarter FY2021 Results, Positioning..
BU
07/30Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Seco..
CI
07/30Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Year..
CI
07/30Takeda Pharmaceutical Company Limites Announces Unaudited Consolidated Earnin..
CI
07/29TAKEDA PHARMACEUTICAL : U.S. Food and Drug Administration Grants Breakthrough Th..
AQ
07/29TAKEDA PHARMACEUTICAL : and Frazier Healthcare Partners Announce Collaboration t..
PU
07/29TAKEDA PHARMACEUTICAL : and Frazier Healthcare Partners Announce Collaboration t..
BU
07/29Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners Announc..
CI
07/29Arrowhead Gets FDA Breakthrough Therapy Designation for ARO-AAT
DJ
07/28TAKEDA PHARMACEUTICAL : TAK-994 Receives Breakthrough-Therapy Designation From F..
MT
07/28TAKEDA PHARMACEUTICAL : U.S. Food and Drug Administration Grants Breakthrough Th..
PU
More news
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
07/30TAKEDA PHARMACEUTICAL : und Frazier Healthcare Partners kündigen Zusammenarbeit ..
07/30TAKEDA PHARMACEUTICAL : et Frazier Healthcare Partners annoncent une collaborati..
07/29TAKEDA PHARMACEUTICAL : y Frazier Healthcare Partners anuncian su colaboración p..
07/20CORONA-BLOG/Vollständig geimpfter Mitarbeiter im Weißen Haus positiv auf Coro..
07/20CORONA-BLOG/Sprunghafter Anstieg der Corona-Infektionen in Frankreich
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 682,00 JPY
Average target price 4 898,00 JPY
Spread / Average Target 33,0%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Mwana Lugogo Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.94%52 641
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348